Clinical Trials Logo

Waldenstroms Macroglobulinemia clinical trials

View clinical trials related to Waldenstroms Macroglobulinemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00832234 Completed - Clinical trials for Waldenstroms Macroglobulinemia

Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia

BDR-WM
Start date: September 2006
Phase: Phase 2
Study type: Interventional

This is a Phase II multicenter study designed to evaluate the safety and efficacy of combination BDR. BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM.